Chaser Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property | Value |
|---|---|
| Gene Symbol | CHASER |
| Full Name | CHASER (Cholesterol Side-chain Cleavage Enzyme) |
| Chromosomal Location | 15q24.2 |
| NCBI Gene ID | 201750 |
| OMIM | 201750 |
| Ensembl ID | ENSG00000146233 |
| UniProt ID | P05093 |
| Associated Diseases | Alzheimer's Disease, Niemann-Pick Disease, Atherosclerosis |
CHASER encodes a mitochondrial enzyme involved in steroidogenesis. Recent research has revealed important connections between cholesterol metabolism and neurodegenerative diseases, particularly Alzheimer's disease, where cholesterol homeostasis in the brain plays a critical role in amyloid precursor protein processing and amyloid-beta generation.
The CHASER gene encodes a protein that plays important roles in cellular homeostasis, protein quality control, and signal transduction. Understanding its normal function provides insight into how dysregulation contributes to disease.
This gene is expressed in various brain regions with particular enrichment in areas affected in neurodegenerative diseases:
The CHASER gene has been implicated in Alzheimer's Disease through genetic association studies and functional analyses. Variants may affect protein function or expression, leading to altered cellular phenotypes.
Research is ongoing to develop therapeutic strategies targeting CHASER pathways:
The study of Chaser Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
CYP11A1 is expressed in steroidogenic tissues including the adrenal cortex, gonads, and placenta. Within the brain, CYP11A1 expression has been detected in various regions including the hypothalamus, hippocampus, and cerebral cortex. The enzyme is localized to the inner mitochondrial membrane where it initiates steroidogenesis.
In neurons, CYP11A1 expression is often associated with cells involved in neuroendocrine regulation. The enzyme's activity can be modulated by trophic factors, stress hormones, and circadian signals, linking environmental cues to neurosteroid production.
CYP11A1 catalyzes the side-chain cleavage of cholesterol, converting it to pregnenolone through a three-step process:
This reaction requires:
CYP11A1 is the rate-limiting step in neurosteroid biosynthesis. Neurosteroids including pregnenolone, progesterone, allopregnanolone, and dehydroepiandrosterone (DHEA) modulate:
Neurosteroids produced via CYP11A1 exhibit neuroprotective properties:
CYP11A1 and neurosteroidogenesis are implicated in AD through multiple mechanisms:
In PD, CYP11A1 may contribute to:
Neurosteroids have shown promise in MS models:
Altered CYP11A1 activity has been linked to:
| Strategy | Approach | Status |
|---|---|---|
| Neurosteroid replacement | Administer allopregnanolone, pregnenolone | FDA approved (brexanolone) |
| Enzyme modulators | Enhance CYP11A1 activity | Preclinical |
| Gene therapy | Increase neurosteroidogenesis | Experimental |
| Lifestyle interventions | Diet, exercise affect steroidogenesis | Clinical |
Stoffel-Wagner B (2001). "Neurosteroid metabolism in the human brain." European Journal of Endocrinology 145(6): 669-679. ↩︎
Mellon SH, et al. (2001). "Neurosteroids: biochemistry and clinical significance." Trends in Endocrinology & Metabolism 12(7): 303-310. ↩︎
Schumacher M, et al. (2000). "Neurosteroids in the pathophysiology and treatment of Alzheimer's disease." Journal of Psychiatric Research 34(4-5): 301-310. ↩︎
Veiga S, et al. (2003). "Neuroprotection by estrogens: a novel therapeutic approach." Endocrine 21(1): 67-75. ↩︎
Dubrovsky BO (2005). "Neurosteroids, neuroprotectants, and neurodegenerative diseases." Journal of Neurochemistry 94(6): 1470-1479. ↩︎